Gene
therapy and viral vector production depend on efficient and reproducible gene
delivery systems. However, performance can vary depending on vector type, cell
state, and production conditions
Pulzar
Technology has demonstrated improved gene delivery efficiency across multiple
viral vector systems and mammalian cell platforms
Recombinant adeno-associated virus (rAAV) vectors produced using Pulzar-treated cells showed
increased functional delivery in a human fibrosarcoma cell line
rAAV-GFP
vectors demonstrated 2.7× higher transduction, measured by fluorescence
intensity relative to control conditions
This substantial improvement in transduction
efficiency potentially enables lower vector doses and improved therapeutic
outcomes
Pulzar application during lentivirus vector production—targeting both the reagent complex and HEK cells—resulted in a 1.8× increase in gene delivery efficiency to hepatocytes
This cumulative effect suggests Pulzar’s potential to enhance vector potency and reduce manufacturing bottlenecks
These findings support Pulzar’s role as a transformative tool in gene therapy workflows, offering improved payload delivery and greater consistency
Download the transfection white paper for detailed methodology, experimental conditions, statistical analysis, and complete datasets
Download white paper